Literature DB >> 26689667

Rationale and protocol of CML study: cognitive and emotional impact of discontinuation of therapy in patients with chronic myeloid leukemia.

Silvia Riva1,2, Ketti Mazzocco1,2, Gabriella Pravettoni1,2.   

Abstract

INTRODUCTION: Discontinuation of therapy can be proposed to patients with chronic myelogenous leukemia (CML) who reach a sustained deep molecular response (DMR) for a minimum and stable period. Today, a considerable number of patients reach a sustained DMR, especially when they are treated with the latest drugs. Although new-generation treatments may provide significant improvement in terms of patient health and health-related quality of life, many patients are uncertain about discontinuation and may refuse a treatment switch.
METHODS: This study is an observational research project aimed at investigating, from a psychological point of view, possible cognitive and emotional components that can influence treatment discontinuation and treatment decisions in a cohort sample of 120 CML patients.
RESULTS: The expected results indicate that cognitive and emotional factors may influence decision-making in this setting and may prevent appropriate risk-and-benefit evaluation of new treatment approaches.
CONCLUSIONS: This is the first study that will analyze in depth all possible psychological variables that can interfere with the medical decision process of treatment discontinuation in CML, providing new insights for clinical practice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26689667     DOI: 10.5301/tj.5000451

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  2 in total

Review 1.  Pediatric Blood Cancer Survivors and Tobacco Use across Adolescence and Emerging Adulthood: A Narrative Review.

Authors:  Marianna Masiero; Silvia Riva; Chiara Fioretti; Gabriella Pravettoni
Journal:  Front Psychol       Date:  2016-03-21

Review 2.  Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.

Authors:  Jorge Cortes; Delphine Rea; Jeffrey H Lipton
Journal:  Am J Hematol       Date:  2018-11-25       Impact factor: 10.047

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.